Ranbaxy Board Approves Spin-off Of Drug Discovery Company
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy Laboratories is moving to "de-merge" its drug discovery activities into a separate company with dedicated resources, the firm announced Oct. 18
You may also be interested in...
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
NEW DELHI - Gurgaon, India-based Ranbaxy Laboratories has delayed plans to spin off its research unit until the second half of the year, but noted during a Jan. 17 press conference that it had settled a key lawsuit over Flomax (tamsulosin) and expanded a development deal with GlaxoSmithKline that will secure earnings momentum
Nicholas Piramal India Inks R&D Deal With Merck
Mumbai-based Nicholas Piramal India Limited inked a research and development deal with Delhi-based Merck subsidiary MSD Pharmaceuticals, NPIL announced Nov. 19